impact of metabolic syndrome on prostate cancer diagnosis and grade in chinese patients undergoing prostate biopsy

1. Abstract

1.1. Objective : Biologic rationale exists for the association between Metabolic Syndrome (MS) and prostate cancer. However, epidemiologic studies have been conflicting. This study aimed to evaluate the association between MS and prostate cancer diagnosis and grade in Chinese patients undergoing prostate biopsy.

1.2. Methods : An observational study was conducted of 890 men who underwent prostate biopsy from two Chinese clinical centers. MS was defined according to the Adult Treatment Panel Ⅲ criteria. Clinicopathological factors including age, PSA, DRE, prostate volume, Body Mass Index (BMI), waist circumference, blood pressure, fasting blood sugar level, lipid profiles, and MS were considered for analysis.

1.3. Results : 890 patients were enrolled with a median age and PSA of 67.5 years and 14.44 ng/ml respectively. 247 patients (27.75%) had MS and 404 patients (45.39%) were diagnosed with prostate cancer. Age, PSA, prostate volume, DRE, BMI and MS were significant predictors for prostate cancer detection. Out of 404 patients with prostate cancer, 200 (49.5%) had Gleason score≥4+3, which include 79(39.5%) had MS. PSA, BMI, and MS were significantly associated with an increased risk of high-grade prostate cancer.

1.4. Conclusion : Presence of MS was associated with a significantly increased risk of diagnosis of overall and high-grade prostate cancer. However, these results need to be evaluated in large-scale prospective cohorts.

2. Keywords: Gleason Score; Prostate Cancer; Metabolic Syndrome; Prostate Biopsy